Eurofins Discovery Announces Aquisition of Sage Client Discovery BioMed

See full Press Release by clicking the link below!

DBM PR 5 July 2022

.pdf

Download PDF • 401KB

Sage Group Represents Solvotrin to License Their Novel ActiveIronTM Product Portfolio

Sage Represents Mateon Therapeutics - Leadership in Novel Vascular Targeted Therapy

Eurofins Discovery Announces Aquisition of Sage Client Discovery BioMed

Kinnov Therapeutics Completes Successful Phase 2 study for Alcohol Use Disorder

Hatchtech appoints Sage Group to divest its FDA-approved Xeglyze® for head lice treatment

Sage Advises Cancer Prevention Pharmaceuticals on Merger with Panbela Therapeutics

Product Opportunity for Rare Hematological Disease - KDFX for Iron Overload Disorder from Dispersol

Opportunity in Cellular Immunotherapy with oNKord Unmodified Natural Killer Cells from Glycostem

SalivaPod - Novel Saliva Sample Collection for a New Era of Diagnostics

Novel Gene Therapy Treatment for Head and Neck Cancer with Impressive Phase III Results in China

The Sage Group Invites You to a Webinar by Axiom Space on November 30, 2021at 11 AM Eastern Time

The Sage Group Advises Cancer Prevention Pharmaceuticals on Transaction for Orphan Drug

Sage Group is attending BioEurope F2F in Leipzig and virtually and will be pleased to meet you F2F! Please click here to setup a call with us!